OptimizeRx (NASDAQ:OPRX) Rating Lowered to “Buy” at Wall Street Zen

OptimizeRx (NASDAQ:OPRX) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Monday.

A number of other analysts have also commented on OPRX. Weiss Ratings lowered OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, May 14th. Stephens cut their target price on shares of OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 13th. Lake Street Capital dropped their price target on shares of OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. B. Riley Financial cut their price objective on shares of OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Finally, Zacks Research cut shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 4th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, OptimizeRx has a consensus rating of “Moderate Buy” and a consensus target price of $13.43.

OptimizeRx Stock Performance

OPRX stock opened at $6.66 on Monday. The company has a 50 day moving average price of $5.47 and a 200 day moving average price of $7.43. OptimizeRx has a fifty-two week low of $4.54 and a fifty-two week high of $22.25. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.37 and a quick ratio of 5.37. The stock has a market capitalization of $124.97 million, a PE ratio of 19.03 and a beta of 1.08.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The firm had revenue of $19.84 million for the quarter, compared to analyst estimates of $18.74 million. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%. Analysts forecast that OptimizeRx will post 0.51 EPS for the current year.

Hedge Funds Weigh In On OptimizeRx

Institutional investors and hedge funds have recently made changes to their positions in the company. Quantbot Technologies LP acquired a new stake in OptimizeRx during the 2nd quarter worth $44,000. BNP Paribas Financial Markets increased its holdings in shares of OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after acquiring an additional 2,215 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in shares of OptimizeRx in the fourth quarter worth about $62,000. Aaron Wealth Advisors LLC acquired a new stake in shares of OptimizeRx during the first quarter worth about $66,000. Finally, Worth Venture Partners LLC bought a new position in shares of OptimizeRx during the 3rd quarter valued at about $220,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.